• Acorn Biolabs, a Canadian healthtech startup, has secured $11 million in funding to advance its regenerative medicine platform. The company's technology allows individuals to collect and store their own stem cells, which can be used for future medical treatments. Acorn Biolabs plans to use the funding to expand its operations, develop new product offerings, and further its research and development efforts.

• Acorn Biolabs' platform enables individuals to collect and cryogenically preserve their own stem cells, which can potentially be used for regenerative therapies in the future. The company's technology is designed to be easy to use and accessible, allowing people to take an active role in their long-term health and wellness. Acorn Biolabs aims to empower individuals to take control of their healthcare and be proactive in preserving their own biological resources.

• The $11 million funding round was led by Whitecap Venture Partners, with participation from other investors. This investment will help Acorn Biolabs accelerate the growth of its business, expand its reach, and continue to innovate in the regenerative medicine space. The company's focus on providing accessible and personalized stem cell preservation services aligns with the growing demand for personalized healthcare solutions and the increasing interest in regenerative therapies.